SCHEMBL24529668

SCHEMBL24529668

CC[C@H](CCC(F)(F)F)NC(=O)N(CC)C(C)(C)c1cccc(-c2ccc3nccn3c2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HCRTR2 O43614 4/20 0.58
▸ RET P07949 4/20 0.44
▸ MCHR1 Q99705 1/20 0.36
▸ NAMPT P43490 4/20 0.35
▸ TGFBR1 P36897 2/20 0.35
▸ DPP4 P27487 1/20 0.35
▸ TGFBR2 P37173 1/20 0.34
▸ CCNT1 O60563 1/20 0.34
▸ CCNA2 P20248 1/20 0.34
▸ CDK2 P24941 1/20 0.34
▸ CDK9 P50750 1/20 0.34
▸ CDK5 Q00535 1/20 0.34
▸ DYRK1A Q13627 1/20 0.34
▸ CDK5R1 Q15078 1/20 0.34
▸ DYRK2 Q92630 1/20 0.34
▸ DYRK1B Q9Y463 1/20 0.34
▸ GRIN2B Q13224 1/20 0.33
▸ PDPK1 O15530 1/20 0.33
▸ FGFR3 P22607 1/20 0.33
▸ KDR P35968 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24529484 1.00 HCRTR2 (0.58) HCRTR2RETMCHR1NAMPTTGFBR1
SCHEMBL29723579 1.00 HCRTR2 (0.58) HCRTR2RETMCHR1NAMPTTGFBR1
SCHEMBL29723804 1.00 HCRTR2 (0.58) HCRTR2RETMCHR1NAMPTTGFBR1
SCHEMBL27179403 0.75 HCRTR2 (0.47) HCRTR2RETMCHR1NAMPTTGFBR1
SCHEMBL24529495 0.75 HCRTR2 (0.47) HCRTR2RETMCHR1NAMPTTGFBR1
SCHEMBL24529170 0.74 HCRTR2 (1.00) HCRTR2RETMCHR1TGFBR1DPP4
SCHEMBL27181016 0.74 HCRTR2 (1.00) HCRTR2RETMCHR1TGFBR1DPP4
SCHEMBL24529173 0.74 HCRTR2 (0.72) HCRTR2RETMCHR1TGFBR1
SCHEMBL27181021 0.74 HCRTR2 (1.00) HCRTR2RETMCHR1TGFBR1DPP4
SCHEMBL24529445 0.73 HCRTR2 (0.64) HCRTR2RETMCHR1TGFBR1DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4262788-B1 UREA OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME LLC (US) 2026-01-21 — — EP claimed
US-20240101555-A1 UREA OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME LLC (US) 2024-03-28 — — US claimed
EP-4262788-B1 UREA OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME LLC (US) 2026-01-21 — — EP disclosed
US-20240101555-A1 UREA OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME LLC (US) 2024-03-28 — — US disclosed
WO-2022132696-A1 UREA OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2022-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101555-A1 UREA OREXIN RECEPTOR AGONISTS HCRTR1, HCRTR2, UTS2R HCRTR2 2/4885RET 335/4885MCHR1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback